What one share of Spero Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. Since our inception in 2013, we have focused our efforts and financial resources on acquiring and developing product and technology rights, building our intellectual property portfolio and conducting research and development activities for our product candidates.
Spero Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.78 |
|---|---|
| Profit | $0.12 |
| Cash and investments | $0.87 |
| Book value | $0.76 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$53.11 | $0.92 | −$38.92 | — | −$73.39 |
| 2016 | $1.07 | −$95.87 | $2.66 | −$95.43 | — | −$145.56 |
| 2017 | $0.77 | −$17.82 | $0.01 | −$15.13 | — | — |
| 2018 | $0.25 | −$2.60 | $0.15 | −$2.63 | — | $6.71 |
| 2019 | $1.00 | −$3.35 | $0.02 | −$2.77 | — | $3.89 |
| 2020 | $0.42 | −$3.52 | $0.01 | −$3.84 | — | $4.51 |
| 2021 | $0.59 | −$2.91 | — | — | — | $2.73 |
| 2023 | $1.96 | $0.43 | — | — | — | $2.02 |
| 2024 | $0.89 | −$1.27 | — | — | — | $0.84 |
| 2025 | $1.13 | $0.15 | — | — | — | $1.05 |
Common questions about Spero Therapeutics
How much does one share of Spero Therapeutics earn?
Over the last 12 months, each share of Spero Therapeutics earned $0.12 of profit on $0.78 of sales, keeping about 16¢ of every $1 (profit margin).
Does Spero Therapeutics pay a dividend?
Spero Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Spero Therapeutics’s book value per share?
Spero Therapeutics’s book value is $0.76 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Spero Therapeutics have?
Each share of Spero Therapeutics has $0.87 of cash and investments, as of June 30, 2026.
Has Spero Therapeutics bought back shares?
Spero Therapeutics’s share count rose about 23253% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.